Core Insights - Harbour BioMed has advanced its global strategic collaboration with AstraZeneca to develop next-generation biotherapeutics, including antibody-drug conjugates and T cell engagers, leveraging both companies' expertise [1][3] Collaboration Details - AstraZeneca will nominate discovery programs to Harbour BioMed annually over the next four years, with the option to license these programs for further development. Harbour BioMed will receive option fees, milestone payments, and tiered royalties on future net sales [2] Company Background - Harbour BioMed is a global biopharmaceutical company focused on discovering and developing novel antibody therapeutics in immunology and oncology, building a robust pipeline through internal R&D, strategic collaborations, and selective acquisitions [4] Technology Platform - The company utilizes its proprietary Harbour Mice technology to generate fully human monoclonal antibodies in various formats, enabling the development of innovative biologics for treating significant medical needs [5]
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology